Bebtelovimab potently neutralizes all SARS-CoV-2 variants of concern - News-Medical.Net

The current study, escribes a new mAb LY-CoV1404 (bebtelovimab) from Eli Lilly, with high neutralization potency with a broad spectrum of activity across all current variants.

New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge, posing formidable challenges to vaccine efficacy and the end of the pandemic. Selective immune and vac… [+7047 chars]

full article...